CIMO vs JAZZ
Chimera Investment Corporation (CIMO) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Chimera Investment Corporation (CIMO) common stock listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
CIMO does not have a complete income-statement cache yet.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
CIMO currently screens at market cap $0. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the CIMO and JAZZ stock pages for the full models.
Not investment advice.